Virology meetings & conferences

4th Pediatric Infectious Diseases Conference - Emerging Infections and Vaccine Dilemmas (PIDC 2013)

17th November 2013 Mumbai, India

The 4th Pediatric Infectious Diseases Conference - Emerging Infections and Vaccine Dilemmas (PIDC 2013) will be held in the city of Mumbai, India on 17th November 2013. The conference provides an opportunity for pediatricians, infectious disease specialists, critical care physicians, oncologists and post graduate students from around the world to receive the latest research, perspectives and treatments of pediatric infectious disease from principal experts in the field. This PID conference features a high-caliber and multi-disciplinary scientific programme featuring groundbreaking information and in-depth examination of the most essential topics that are needed in practical management of children with infectious diseases.

The scientific programme will cover a thorough and detailed journey through emerging infections, travel related infections for children returning from abroad, common problems of infestation and eosinophilia, recurrent infections, surgery related infections. Upcoming dilemmas in vaccinations such as intussusception and rotavirus vaccine, re-emerging pertussis, update in immunization in pregnant women will be discussed in depth. Prevention of emerging MDR infections with antibiotic stewardship, biofilms and catheter care will be addressed. The entire programme is in form of interactive case discussions, panel discussions and state of the art lectures.

Pseudotype Viruses - Applications and Troubleshooting

Wednesday, 02 October 2013 09:00 - 17:00 London United Kingdom

Pseudotype viruses are rapidly establishing themselves as important research and diagnostic tools of basic and clinical scientists facilitating the detailed study of individual viral genes, host cell receptors and highly pathogenic viruses, circumventing the need for high-level biosafety containment. The switching of surface envelope proteins expressed on the surface of these pseudotypes enables them to be used as surrogate viruses in neutralization/antiviral screening assays and for the study of cell–virus receptor interactions. This meeting encompasses the many diverse applications of pseudotype technologies from a practical, translational and public health perspective.

Who Should Attend

• Public and animal health scientists.

• Individuals establishing diagnostic assays for viruses.

• Epidemiologists, virologists, immunologists, R&D, pre-clinical vaccinologists.

Contact Details

Email: enquiries@euroscicon.com

Web: www.lifescienceevents.com

Chikungunya 2013

28-30 October, 2013 Langkawi Island, Malaysia

The recent re-emergence of Chikungunya virus led to millions of affected people worldwide. For the first time, local transmission from mosquitoes were reported outside the tropics, in Italy and France. As the global distribution of Aedes mosquito vectors continues to expand, Chikungunya is now a global threat, and no longer a relatively neglected infection confined to the tropics.

We are therefore pleased to invite all those interested in Chikungunya to this major conference focusing on Chikungunya and related alphaviruses. A broad range of topics will be addressed by leading experts, and the conference will appeal to virologists, clinicians, epidemiologists and entomologists. There will also be opportunities for selected participants to present papers at oral and poster sessions, including a number of Young Investigator Awards.

The conference will be organised jointly by the Tropical Infectious Diseases Research and Education Centre, of University Malaya in Malaysia, and the Integrated Chikungunya Research (ICRES) consortium, funded by the European Union Seventh Framework Programme.

For further details and updates, please e-mail us. To be put on our mailing list, please register your e-mail with the Secretariat at:

Chikungunya 2013 Secretariat
Tropical Infectious Diseases Research and Education Centre
Faculty of Medicine
University Malaya
Kuala Lumpur 50603
Malaysia
Tel: (60) 3 7967 6670/6661
Fax: (60) 3 7967 6678
E-mail: chikv2013@um.edu.my

Meningitis and Septicaemia in Children and Adults 2013

Tuesday 5 and Wednesday 6 November 2013 Royal Society of Medicine, London, United Kingdom

Our ninth conference will bring together internationally renowned experts from a range of specialties in the UK and abroad to address the most important issues of the day, including burden of illness, recognition and treatment, vaccine development, vaccine implementation and public health policy.

Attracting delegates from around the world, this conference is a key event in the calendar for some of the foremost scientists and clinicians and provides an excellent opportunity to discuss the latest developments within the field.

3rd Global Congress for Consensus in Pediatrics & Child Health

February 13-16, 2014 Bangkok, Thailand

The concept for the CIP congress and program was developed for Pediatricians working in Primary and Secondary Care, as well as for specialists in the diverse areas of Pediatrics, Pediatric Surgeons, Family Medicine Doctors, General Practitioners, Researchers and Policy Makers

Main Topics

Primary Care

Neonatology

Pediatric Allergy & Immunology

Critical & Intensive Care

Pediatric Dermatology

Emergency Medicine

Pediatric Education

Pediatric Endocrinology

Pediatric Gastroenterology

Social Pediatrics

Pediatric Genetics

Hematology & Oncology

Infectious Diseases and Vaccinology

Pediatric Nephrology

Pediatric Neurology

Developmental-Behavioral Pediatrics

Pulmonology and Sleep Medicine

Pediatric Psychiatry

Pediatric Radiology

Pediatric Rheumatology

Pediatric Nutrition

Pediatric Sports Medicine

Adolescent Health

Surgery and its specialties

Rare and Orphan diseases

Pharmacology and Toxicology

Contact Us

Paragon Conventions
Tel: +41 (0)22 533 0948 Fax: +41 (0)22 580 2953
Email: cip@cipediatrics.org

Advances in Plasmodium vivax Malaria Research

May 28 - 29, 2013 Barcelona, Spain

Presented by The New York Academy of Sciences, the "la Caixa" Foundation, B-DEBATE, Barcelona Institute for Global Health (ISGlobal), and the Barcelona Centre for International Health Research (CRESIB)

Malaria accounts for approximately 250 million clinical cases and nearly 1 million deaths annually, mostly in children, in 109 countries. There has been growing evidence that Plasmodium vivax is the most widely distributed malaria parasite, responsible for a significant burden of global disease and accounting for the majority of malaria cases in Latin America and Asia. Despite the increasing awareness that the overall burden, economic impact, and severity of P. vivax disease have been underestimated, this species remains underrepresented in the scientific literature and professional fora.

This 2-day conference will convene a global community of researchers to discuss P. vivax molecular biology and genomics, host–parasite interactions, novel research techniques (e.g., 'omics) to overcome barriers to in vitro, in vivo, and clinical study of P. vivax; drug resistance and drug discovery; and recent clinical trial and in-field efforts in P. vivax prevention, treatment, control, and elimination.

2nd Li Ka Shing Institute of Virology Symposium: Interactions Between the Immune System and Pathogens

May 30 & 31, 2013 Edmonton, Alberta, Canada

Symposium with national and international Speakers in the field of virology. Two-day conference with ample opportunity for networking and a large poster session.

Nanotechnologies in Cancer Diagnosis, Therapy, and Prevention

June 11 - 13, 2013 Moscow, Russia

World Trade Center Moscow Congress Center

Presented by The New York Academy of Sciences, the Mushett Family Foundation, and the Skolkovo Institute of Science and Technology

Harnessing principles from chemistry, biology, physics, and engineering, nanotechnology is a multidisciplinary field still in its infancy. Throughout the past decade, nanoparticles and specifically nanoparticle drug delivery systems, have emerged at the forefront of cancer therapies.

Nanotechnology has helped to design and fabricate micro-scale devices, including nanoparticle drug delivery systems able to target tumors and other cancerous tissue. Nanotechnology is also being explored to generate other novel techniques to design biomarkers, immunotherapy, and vaccine development for cancer.

Featuring keynote address by Nobel Laureate Robert Y. Tsien, PhD, this 2.5-day conference will discuss: nanodiagnostics for cancer biomarkers and imaging, nanoparticle toxicity and safety; nanovaccines and nanoimmunotherapeutics; the challenges of targeted delivery in tumors; and nanoparticle-based gene therapy. A discussion of these topics will serve to enhance the translation of research discoveries into improved cancer diagnostic and treatment strategies.

Options for the Control of Influenza VIII

September 5-10, 2013 Cape Town, South Africa

Held every 3 years, Options for the Control of Influenza is the largest international scientific conference exclusively devoted to influenza.  Options VIII will showcase recent advances in the basic science and control and prevention of influenza.  Whatever your domain of expertise – virology, veterinary medicine, human medicine, public health policy, industry or journalism – Options for the Control of Influenza VIII is the premier conference bringing together experts dedicated to all aspects of influenza.  Presentation formats will include keynote addresses, invited lectures, scientific workshops, abstract presentations, satellite meetings and poster sessions.

The 2013 conference will allow delegates to experience the beauty and warm hospitality of Cape Town, South Africa. Delegates at Options VIII will experience an unforgettable mix of modern and traditional African ambience. Options VIII will highlight these characteristics along with cultural events strategically placed within the agenda. In addition, delegates will be provided an opportunity to participate in many pre-conference or post-conference tours on their own to encounter nature and history and create memories to treasure.

Conference Goals and Objectives:

•Provide comprehensive scientific guidance for all stakeholders involved in influenza prevention, control, and treatment, including seasonal pandemic planning

•Promote genuine international and multidisciplinary collaboration, supporting the full spectrum of influenza research from basic science to the development of new vaccines and antiviral agents to epidemiology and control programs

•Provide a collegial atmosphere where scientists working in public health and scientists working in agricultural or veterinary agencies may exchange information to develop collaborative approaches to the control and prevention of pandemic influenza

•Maximize the opportunities for informal discussions and exchange of ideas between representatives of government agencies, academia, and industry

Join us in Cape Town and experience this premier event!

For questions contact us at info@controlinfluenza.com.

Progressive Multifocal Leukoencephalopathy

June 19 - 20, 2013 The New York Academy of Sciences

Presented by the Progressive Multifocal Leukoencephalopathy Consortium and The New York Academy of Sciences

Progressive Multifocal Leukoencephalopathy (PML) is, in the general population, a rare but serious demyelinating disease of the brain, often resulting in severe disability or death and is caused by infection of oligodendrocytes by the JC polyomavirus (JCV). It is believed that fifty to sixty percent of the population is sero-positive for JCV, indicating exposure to the virus. Despite the high prevalence of JCV infection in the human population, which typically leads to a chronic, asymptomatic infection, incidence of PML in the general population is very low. The pathogenesis of PML is not well understood. It is believed that the development of PML, while dependent on the presence of JCV, is the result of a confluence of viral and host risk factors, which may include an altered or compromised immune system such as in individuals with HIV-1 infection/acquired immune deficiency syndrome (AIDS), or patients undergoing chronic immunosuppressive therapies after organ transplantation, for treatment of lymphomas, or for autoimmune conditions, such as MS.

This 2-day conference will bring together basic science researchers, clinicians, physicians, epidemiologists, and regulatory experts from academia, industry, and government to address novel issues, current challenges, and future directions of basic and clinical research relevant to the mitigation, potential future cure, and risk stratification of PML. Topics of discussion will include JCV virology, PML pathogenesis, risk stratification and disease diagnosis and management. The meeting will feature a series of plenary lectures, short talk presentations selected from submitted abstracts, a poster session, and a closing panel discussion.